<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  
  
  
  <meta name="generator" content="Wowchemy 4.8.0 for Hugo">
  

  

  
  

  
  
  
  
  
    
    
    
  
  

  

  
  
  
    
  
  <meta name="description" content="Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance.">

  
  <link rel="alternate" hreflang="en-us" href="https://seandavi.github.io/publication/pmid-24292683/">

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  

  
  
  
  <meta name="theme-color" content="#3f51b5">
  

  
  
  
  <script src="/js/mathjax-config.js"></script>
  

  
  
  
  
    
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/atom-one-light.min.css" crossorigin="anonymous" title="hl-light">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/atom-one-light.min.css" crossorigin="anonymous" title="hl-dark" disabled>
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.css" integrity="sha512-1xoFisiGdy9nvho8EgXuXvnpR5GAMSjFwp40gSRE3NwdUdIMIKuPa7bqoUhLD0O/5tPNhteAsE5XyyMi5reQVA==" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.2.2/lazysizes.min.js" integrity="sha512-TmDwFLhg3UA4ZG0Eb4MIyT1O1Mb+Oww5kFG0uHqXsdbyZz9DcvYQhKpGgNkamAI6h2lGGZq2X8ftOJvF/XjTUg==" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-93043521-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-93043521-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png">

  <link rel="canonical" href="https://seandavi.github.io/publication/pmid-24292683/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="twitter:site" content="@seandavis12">
  <meta property="twitter:creator" content="@seandavis12">
  
  <meta property="og:site_name" content="seandavi(s12)">
  <meta property="og:url" content="https://seandavi.github.io/publication/pmid-24292683/">
  <meta property="og:title" content="Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma | seandavi(s12)">
  <meta property="og:description" content="Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance."><meta property="og:image" content="https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png">
  <meta property="twitter:image" content="https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2021-08-21T20:01:46&#43;00:00">
    
    <meta property="article:modified_time" content="2021-05-08T15:13:09-06:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://seandavi.github.io/publication/pmid-24292683/"
  },
  "headline": "Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma",
  
  "datePublished": "2021-08-21T20:01:46Z",
  "dateModified": "2021-05-08T15:13:09-06:00",
  
  "author": {
    "@type": "Person",
    "name": "Z. Kang"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "seandavi(s12)",
    "logo": {
      "@type": "ImageObject",
      "url": "https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance."
}
</script>

  

  


  


  





  <title>Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma | seandavi(s12)</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class=" ">

  
  
  
  
    <script>const isSiteThemeDark = false;</script>
  
  
  <script src="/js/load-theme.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">seandavi(s12)</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">seandavi(s12)</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>About</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts"><span>Posts</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#talks"><span>Talks</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#publications"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/project/"><span>Projects</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      

      

    </ul>

  </div>
</nav>



  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span ><a href="/authors/z.-kang/">Z. Kang</a></span>, <span ><a href="/authors/y.-yu/">Y. Yu</a></span>, <span ><a href="/authors/y.-j.-zhu/">Y. J. Zhu</a></span>, <span ><a href="/authors/s.-davis/">S. Davis</a></span>, <span ><a href="/authors/r.-walker/">R. Walker</a></span>, <span ><a href="/authors/p.-s.-meltzer/">P. S. Meltzer</a></span>, <span ><a href="/authors/l.-j.-helman/">L. J. Helman</a></span>, <span ><a href="/authors/l.-cao/">L. Cao</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    December 2014
  </span>
  

  

  

  
  
  
  <span class="middot-divider"></span>
  <a href="/publication/pmid-24292683/#disqus_thread"></a>
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  





<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/pmid-24292683/cite.bib">
  Cite
</button>















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Oncogene</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    








<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://seandavi.github.io/publication/pmid-24292683/&amp;text=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://seandavi.github.io/publication/pmid-24292683/&amp;t=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma&amp;body=https://seandavi.github.io/publication/pmid-24292683/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://seandavi.github.io/publication/pmid-24292683/&amp;title=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma%20https://seandavi.github.io/publication/pmid-24292683/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://seandavi.github.io/publication/pmid-24292683/&amp;title=Downregulation%20of%20IGFBP2%20is%20associated%20with%20resistance%20to%20IGF1R%20therapy%20in%20rhabdomyosarcoma" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  





<section id="comments">
  
    
<div id="disqus_thread"></div>
<script>
  var disqus_config = function () {
    
    
    
  };
  (function() {
    if (["localhost", "127.0.0.1"].indexOf(window.location.hostname) != -1) {
      document.getElementById('disqus_thread').innerHTML = 'Disqus comments not available by default when the website is previewed locally.';
      return;
    }
    var d = document, s = d.createElement('script'); s.async = true;
    s.src = 'https://' + "seandavi-github-io" + '.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
  })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
<a href="https://disqus.com" class="dsq-brlink">comments powered by <span class="logo-disqus">Disqus</span></a>


  
</section>










  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/mermaid/8.8.0/mermaid.min.js" integrity="sha512-ja+hSBi4JDtjSqc4LTBsSwuBT3tdZ3oKYKd07lTVYmCnTCor56AnRql00ssqnTOR9Ss4gOP/ROGB3SfcJnZkeg==" crossorigin="anonymous" title="mermaid"></script>
      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/highlight.min.js" integrity="sha512-TDKKr+IvoqZnPzc3l35hdjpHD0m+b2EC2SrLEgKDRWpxf2rFCxemkgvJ5kfU48ip+Y+m2XVKyOCD85ybtlZDmw==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/r.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/python.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/javascript.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/html.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.js" integrity="sha512-SeiQaaDh73yrb56sTW/RgVdi/mMqNeM2oBwubFHagc5BkixSpP1fvqF47mKzPGWYSSy4RwbBunrJBQ4Co8fRWA==" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://seandavi-github-io.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/wowchemy.min.434af0ebce9e15b273b954d65feb39c7.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  

  <p class="powered-by">
    © 2016-2020
  </p>

  
  






  <p class="powered-by">
    
    Published with
    <a href="https://wowchemy.com" target="_blank" rel="noopener">Wowchemy</a>  —
    the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">
    open source</a> website builder that empowers creators.
    

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
